When the U.S. Food and Drug Administration (FDA) weighed the approval of the autoimmune disease drug Tavneos several years ago, internal agency experts issued stark warnings. According to comprehensive federal records, scientists argued that绿the greenlight was premature, pointing directly to a concerning deficit in safety data provided by the manufacturer. Yet, following a well-trodden regulatory path, the agency approved the medication in 2021 with a critical stipulation: the manufacturer must conduct an exhaustive, years-long post-market safety study while the drug generated revenue on the commercial market.
Years later, that mandatory follow-up study remains mired in delays, mirroring a systemic vulnerability across the American healthcare apparatus. As of last autumn, only 21 of the targeted 300 patients had been successfully enrolled, according to federal regulatory postings and agency correspondence. Meanwhile, the FDA has identified dozens of cases of serious liver damage potentially linked to the medication—precisely the sort of long-term safety signal the post-market trial was designed to evaluate.
The trajectory of Tavneos exposes deep systemic risks within the FDA’s reliance on post-approval mandates, illuminating a landscape where delayed research leaves patients, physicians, and payers navigating a fog of uncertainty regarding the actual safety and efficacy of high-cost medical products.
A Systemic Pattern of Delayed Oversight
An extensive analysis of FDA tracking data reveals that hundreds of post-market studies mandated for pharmaceutical drugs, biologics, and medical devices are routinely running behind schedule. In numerous instances, required research has stalled for more than a decade, or manufacturers have struggled simply to establish a workable study protocol.
Public health researchers and independent cardiologists note that post-market requirements have frequently proven to be toothless instruments. While companies collect billions in revenue, the promised post-approval evaluations lag, creating a regulatory gap where products remain widely available despite unverified benefits or hidden risks.
This regulatory compromise is rooted in a fundamental balancing act. Accelerating access to novel treatments can save or dramatically improve lives, particularly for patients facing grim medical prognoses with few alternative options. Because clinical trials prior to approval are often limited in size and duration, the complete risk-benefit profile of a therapy typically emerges only after thousands of patients use the product in real-world settings over extended periods.
However, leaning heavily on post-approval studies to answer lingering questions shifts the burden of proof onto the consuming public. Patients stake their health and lives on these interventions, while insurance companies, government health programs like Medicare and Medicaid, and employers shoulder enormous financial costs, frequently rewarding manufacturers for products whose ultimate value remains unproven.
Case Studies in Regulatory Stagnation
The database of delayed commitments spans a wide array of therapeutics and medical technologies, impacting vulnerable patient populations across various medical specialties.

Among the delayed products is the CustomFlex Artificial Iris, a specialized ocular prosthesis meant to replace damaged or missing irises. Although the protocol for a pediatric post-approval study was accepted in 2019 to monitor patients across a five-year span, federal records indicate that zero patients had been enrolled as of August. Representatives for the German manufacturer and its U.S. distributor note that the extreme rarity of the underlying eye condition, aniridia, presents monumental recruitment hurdles, and they are actively consulting the FDA to establish alternative verification pathways.
Similarly, a mandated post-market study evaluating the safety of the COVID-19 antiviral treatment Paxlovid in pregnant women missed its initial completion milestone at the end of 2024. Manufacturer Pfizer stated it is actively collaborating with the FDA to submit findings as soon as practicable.
In the device sector, the Scandinavian Total Ankle Replacement (STAR) system encountered profound enrollment shortfalls. While the clinical trial was designed to track a minimum of 500 subjects following its 2009 approval, only 142 patients were ultimately enrolled. Alarmingly, nearly half of those participants experienced one or more adverse events, resulting in dozens of surgical revisions, removals, or reoperations.
Even specialized opioid medications have fallen into this regulatory limbo. When the FDA approved Oxaydo—an oxycodone product engineered to deter abuse—in 2011, it mandated a post-market study to measure whether the drug successfully curbed misuse, overdose, and addiction, with a final report due in 2016. By 2022, the agency issued a failure-to-respond letter. The issue ultimately became moot when marketing rights shifted across multiple entities and the original patents expired, leading the manufacturer to discontinue the drug entirely.
The Financial Incentive of Delay
For pharmaceutical and medical device corporations, delaying post-market research carries minimal financial penalty while preserving lucrative revenue streams. Companies are legally permitted to market and sell their products while required studies crawl along or remain stalled.
A landmark analysis by the Department of Health and Human Services (HHS) Office of Inspector General underscored the financial scale of this issue, estimating that Medicare and Medicaid spent more than $18 billion between 2018 and 2021 alone on accelerated approval drugs whose confirmatory trials had missed their original completion deadlines.
The stakes are further amplified by recent policy shifts designed to expedite drug approvals. In February, FDA leadership announced that a single clinical trial would become the "default requirement" for agency approvals, replacing the traditional standard of two trials. While federal officials defended the shift as a mechanism to slash corporate development costs and speed vital medications to market without compromising safety, independent epidemiologists and researchers warned that shrinking pre-approval scrutiny places an unsustainable burden on an already fragile post-approval monitoring system.
Federal health officials defend the current framework, noting that post-market study delays can occasionally stem from legitimate scientific, logistical, or recruitment challenges. Representatives for the Department of Health and Human Services emphasize that a delayed study should not automatically be interpreted as evidence that a medical product harbors an unresolved safety or effectiveness defect, maintaining that every instance requires an individualized, case-specific review.
High-Stakes Battles Over Efficacy and Safety
The consequences of unverified post-market commitments are acutely visible in landmark approvals that have sparked fierce internal dissent within the federal regulatory agency itself.

In 2016, the FDA granted accelerated approval to Exondys 51, a high-cost treatment for Duchenne muscular dystrophy, a degenerative genetic disorder primarily affecting young boys. Agency scientists aggressively opposed the greenlight, arguing that the drug’s clinical benefit was entirely unproven. In an internal memo, senior drug evaluation official Ellis Unger warned that thousands of patients and their families would be subjected to physical hardship and financial risk in exchange for "false hope."
Despite warnings from dissenting scientists that the FDA had historically struggled to withdraw marketing authorization for drugs that failed post-market verification, Exondys 51 advanced to market. Nearly a decade post-approval, and more than five years past its original final report deadline, the confirmatory study was officially categorized as delayed due to patient recruitment difficulties. Meanwhile, the drug climbed to become one of the most expensive therapeutics in the United States, commanding annual costs between $750,000 and $1.5 million per patient and generating over half a billion dollars in annual sales for manufacturer Sarepta Therapeutics. Company representatives stated that the trial achieved full enrollment in 2023 and that initial data analyses would be released late this year.
The Mounting Crisis Surrounding Tavneos
Nowhere are the vulnerabilities of the post-market framework more vividly illustrated than in the unfolding regulatory battle over Tavneos. Approved in 2021 to treat severe manifestations of ANCA-associated vasculitis—a group of rare autoimmune conditions where the immune system attacks and destroys small blood vessels—the drug was pushed through despite internal expert warnings regarding limited safety data.
The mandated post-market study, designed to monitor 300 patients over five-year intervals to evaluate potential drug-induced liver injury, has severely stalled. As of mid-summer, only a small fraction of the required patient cohort had been enrolled, with manufacturer Amgen pointing to severe recruitment hurdles driven by patient reluctance to risk receiving a placebo when approved alternative therapies exist.
Simultaneously, the regulatory foundation of the drug has fractured internationally and domestically. European Union health authorities officially revoked their marketing authorization for Tavneos. Domestically, the FDA initiated formal proceedings to withdraw approval of the drug entirely, alleging that the original clinical trials sponsored by ChemoCentryx (subsequently acquired by Amgen for $3.7 billion) failed to demonstrate substantial evidence of effectiveness and that data results had been improperly manipulated.
Amgen has aggressively contested the FDA’s assertions, maintaining that the underlying clinical data remain scientifically valid, that the therapeutic benefits of Tavneos substantially outweigh its risks, and that the drug remains a vital option for patients suffering from severe vasculitis. The company continues to negotiate with federal regulators regarding both the ongoing safety study and the preservation of the drug’s market authorization.
As regulatory pathways grow increasingly streamlined to accelerate commercial access, the widening gap between initial market entry and rigorous post-market validation underscores an urgent public health dilemma. Without strict enforcement mechanisms and timely compliance from manufacturers, the promise of modern medicine risks operating in a dangerous regulatory vacuum—leaving patients to bear the unseen costs of unverified safety and delayed science.








